| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8739661 | Journal of Clinical Virology | 2018 | 7 Pages |
Abstract
12-month VL suppression with Complera/Stribild was high, suggesting that OPODs remain options even for experienced patients. Clinicians should consider resistance history before switching to OPODs and continue to focus on improving adherence.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Rebecca Reece, Allison Delong, Matthew D'Antuono, Karen Tashima, Rami Kantor,